GeneGo and Spotfire Partner to Deliver Faster Genomics and Chemistry Analysis

GeneGo, Inc. and Spotfire have announced that the companies' flagship products are fully integrated.

The integrated products can allow users to analyze genomics data, including gene expression and proteomics in Spotfire DecisionSite, and launch MetaCore to perform pathway and network analysis.

DecisionSite users can also automatically upload chemical compounds into MetaCore and MetaDrug in order to study their biological effects, including mode of action and potential toxicity. The analyzed data can be sent back to DecisionSite, allowing the user to search for additional experiments run in house.

"The integration between DecisionSite and MetaCore and MetaDrug provides our mutual customers with a more powerful environment, improving workflow and accelerating discovery from their experimentation and content," said Christian Marcazzo, Senior Director of Life Science Analytics for Spotfire.

"This integration is a brilliant demonstration of the flexibility of the DecisionSite platform to evolve with the changing needs of our pharmaceutical industry customers."

"We received numerous requests from our mutual customers for seamless integration with Spotfire. This integration is unique as both GeneGo's and Spotfire's products enable concurrent analysis and display of both biological and chemistry data," said Julie Bryant, Vice President of Business Development at GeneGo.

"GeneGo has an open partnering philosophy and we always look forward for expansion of our product integration space. We are very pleased with the current project with Spotfire, the dominant player in the data analysis market."